TLP
IRWD icon

Tri Locum Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Tri Locum Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,326
Closed -$99.4K – 40
2023
Q3 		$99.4K Buy
+10,326
New +$101K 0.03% 56

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Tri Locum Partners's IRWD Position: Q4 2023 in Review

Tri Locum Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2023, closing a stake of 10,326 shares — an estimated $99.4K sold.

Tri Locum Partners first reported a position in IRWD in Q3 2023 and held it in 1 quarter. The position peaked at $99.4K in Q3 2023. 251 funds tracked by Wall St. Rank hold IRWD as of Q4 2023.

  • Tri Locum Partners reported no remaining Ironwood Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 10,326 Ironwood Pharmaceuticals shares in Q4 2023, an estimated $99.4K.
  • Tri Locum Partners first reported a position in Ironwood Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Tri Locum Partners's Ironwood Pharmaceuticals position peaked at $99.4K in Q3 2023.
  • 251 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.